![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Ledipasvir/Sofosbuvir for the Treatment of Patients With
Chronic Genotype 4 or 5 HCV Infection
|
|
|
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Armand Abergel1, Veronique Loustaud-Ratti2, Sophie Metivier3, Deyuan Jiang4, Kathryn Kersey4, Steven J. Knox4, Evguenia Svarovskaia4, Philip S. Pang4, Didier Samuel5, Tarik Asselah6
1Centre Hospitalier Universitaire-Estaing, Universite d'Auvergne, Clermont-Ferrand, France; 2Centre Hospitalier Universitaire-Limoges, Inserm UMR 1092, Limoges, France; 3Centre Hospitalier Universitaire-Purpan, Toulouse, France; 4Gilead Sciences, Inc., Foster City, California, USA; 5Hôpital Paul Brousse, Universite Paris Sud, Villejuif, France; 6University Paris Diderot and INSERM U773, Beaujon Hospital, Clichy, France
![EASL1.gif](../images/042915/042915-6/EASL1.gif)
![EASL2.gif](../images/042915/042915-6/EASL2.gif)
![EASL3.gif](../images/042915/042915-6/EASL3.gif)
![EASL4.gif](../images/042915/042915-6/EASL4.gif)
![EASL5.gif](../images/042915/042915-6/EASL5.gif)
![EASL6.gif](../images/042915/042915-6/EASL6.gif)
![EASL7.gif](../images/042915/042915-6/EASL7.gif)
![EASL8.gif](../images/042915/042915-6/EASL8.gif)
![EASL9.gif](../images/042915/042915-6/EASL9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|